Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for Duchenne muscular dystrophy and other diseases with significant unmet medical need. The company's primary focus is Deramiocel, a cell therapy comprising cardiosphere-derived cells designed to reduce inflammation and fibrosis in cardiac and skeletal muscle, targeting adolescents and young adults with DMD. Capricor also operates a proprietary exosome platform called StealthX™ for therapeutic and vaccine development. The company generates revenue through exclusive distribution partnerships, including agreements with Nippon Shinyaku for the United States and Japan, which provide product revenue sharing and milestone payments upon achievement of specified sales thresholds, while operating cGMP-qualified manufacturing facilities and maintaining licensed technology from academic institutions.
| USD millions | FY2025 |
|---|---|
| Revenue | 0 |
| Net Income | -105 |